Asthma treatment

201. – May 13, 1999 POYDRAS DANCER PLANS TO DIG LIFE Combine dance steps, acting talent and an interest in archaeology and what do you get? Poydras native Tiffany Starks. Starks, 18, has been performing since she was 2. Now a freshman at Louisiana State University studying anthropology, she can be seen in a nationally televised commercial and has a healthy sense of what she wants to do with her life and her talent. “I’ve always loved it. Always, ” Starks said of performing. She graduated from …. Times, The (London, England) – September 5, 1998 Zeneca pays Pounds 117m for Australian firm, Business Roundup ZENECA has paid Pounds 117 million for the pharmaceuticals business of the former ICI Australia, a deal that has been delayed by months of wrangling over price. Negotiations began when ICI, Zeneca’s former parent, decided to sell its Australian business in the first half of 1997. The sale of ICI’s 62. 4 per cent stake in ICI Australia, since renamed Orica, was completed in July last year. The Australian pharmaceuticals business essentially acts as Zeneca’s ….. (USA) – June 15, 2009 FDA Requests Labeling Change for Leukotriene Modifiers FDA Requests Labeling Change for Leukotriene Modifiers Fri, 12 Jun 2009 The U. S. Food and Drug Administration today provided further updated safety information on a class of asthma drugs known as leukotriene modifiers. FDA has requested that manufacturers include a precaution in the drug prescribing information (drug labeling) regarding neuropsychiatric events (behavior, mood changes) that have been reported in some persons taking montelukast (Singulair), zafirlukast (Accolate), ….. (LA) – April 21, 2005 Rules for asthma management may change By Sarah Crooks Clancy sclancy@thetowntalk. com (318) 487-6419 Mild, chronic asthma sufferers shouldn’t throw out their daily medications yet. But a new study published last week in The New England Journal of Medicine suggests that many people with mild chronic asthma need to inhale anti-inflammatory steroids only after experiencing an attack. “Only 20 to 25 percent of asthmatics fit in that group, ” said Dr. Benjamin B. Close of Louisiana ….. Evening Standard, The (London, England) – August 6, 1998 Evening Standard: Business Day: Sterling and millennium bug dent Zeneca HIT by the strong pound and the cost of preparing for the millennium, profits at pharmaceuticals group Zeneca slipped by 2% to pounds 654 million over the first half. Chief executive Sir David Barnes said sterling wiped pounds 81 million from operating profits and is likely to cost pounds 110 million for the full year. Preparing computer systems for the year 2000 bug cost pounds 20 million and could total pounds 40 million for the full year. Group sales were up by 5% to pounds 2. 9 ….. Hamilton Spectator, The (Ontario, Canada) – December 8, 1997 Q&A Ask the health experts: New drugs promise better asthma control A new class of drugs for asthma, the first major medical advance in a generation, promises better control of the increasingly prevalent disease. The new drugs, called leukotriene receptor antagonists, are more precise in their action than inhaled corticosteroids, the drugs currently at the forefront of treatment. And they’re tablets, which are bound to be more acceptable than inhalers to children and teens. Leukotriene receptor antagonists include the just-approved drug ….. Times, The (London, England) – June 27, 1995 US launch for Valtrex GLAXO WELLCOME has received approval from the US Food and Drug Administration to sell Valtrex, its new shingles treatment, the company announced yesterday. The drug is the successor to Zovirax, the most widely used medication of its kind. Zovirax, whose patents expire in Britain this year and in America in 1997, had worldwide sales of Pounds 900 million in 1994. Zeneca Pharmaceuticals, meanwhile, said it has sought regulatory approval in Britain for Accolate, a new asthma treatment ….. 208. (USA) – April 3, 2006 Dr. Mitchell Glass Joins TOPIGEN’s Scientific Advisory Board TOPIGEN Pharmaceuticals, Inc. , a biopharmaceutical company specializing in innovative respiratory therapeutics, today announced the appointment of Dr. Mitchell Glass to its Scientific Advisory Board (SAB). Dr. Glass is a pulmonary and critical care specialist and recognized expert in developing drug products for pulmonary and inflammatory-related disorders. “We welcome Dr. Glass to TOPIGEN’s SAB, ” said Dr. Paolo ….. – March 27, 2008 FDA investigates Singulair risk The U. S. Food and Drug Administration said it is investigating reports of suicidal behavior in patients taking the asthma drug Singulair. Singulair, which is made by Merck, is used to treat asthma, the symptoms of allergic rhinitis and to prevent exercise-induced asthma, the FDA said Thursday. Merck has been working with the FDA over the past year to update prescribing information and patient information for Singulair to include the the possible risk of tremors, depression, ….. New Hamburg Independent (Ontario, Canada) – September 15, 2004 Brand-name revenue helps develop new drugs I read with interest the article by CPGA president Jim Keon (Brand vs. Generic, August 11). The member companies of Canada’s Research-Based Pharmaceutical Companies (Rx and D) invest heavily in the research and development (R and D) of new medicines that treat and cure a range of diseases. In 2003, Rx and D member companies invested over $1 billion in R and D. In recent years, advances have included Heptovir, a new medication for the treatment of chronic hepatitis-B; ….